Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Practice Patterns of SGLT2 Inhibitor Use in Stem Cell Transplantation and CART Cell Therapy: A Study from the EBMT Transplant Complications Working Party

Christian R Schultze-Florey, Mouad Abouqateb, Christophe Peczynski, William Boreland, Pascale Ambron, Alberto Mussetti, Christian Koenecke, Charlotte Graham, Helene Schoemans, Olaf Penack, Ivan Sergeevich Moiseev, Zinaida Peric

Blood (2024) 144 (Supplement 1): 7605.

https://doi.org/10.1182/blood-2024-202598

Published: 2024

Journal Articles

Developing Evidence-Based Guidelines for Optimal Patient Communication Prior and Post Allogeneic Stem Cell Transplantation

Anne Herrmann, Helene Schoemans, Eva Wilhelm, Guy Tavori, Nada Hamad, Meredith A. Cowden, Anna Barata, Francis A. Ayuk, Wolfgang Herr, Joerg Halter, Stephanie Lee, Daniel Wolff

Blood (2024) 144 (Supplement 1): 4917.

https://doi.org/10.1182/blood-2024-199052

Published: 2024

Journal Articles

ATG or Post-Transplant Cyclophosphamide to Prevent Gvhd in Matched Unrelated Stem Cell Transplantation? - a Registry Analysis By the EBMT Transplant Complications Working Party

Olaf Penack, Mouad Abouqateb, Christophe Peczynski, William Boreland, Nicolaus Kröger, Matthias Stelljes, Tobias Gedde-Dahl, Igor Wolfgang Blau, Thomas Schroeder, Urpu Salmenniemi, Aleksandr Kulagin, Sr., Regis Peffault De Latour, Stephan Mielke, Jürgen Finke, Ivan Sergeevich Moiseev, Helene Schoemans, Christian Koenecke, Zinaida Peric

Blood (2023) 142 (Supplement 1): 3558.

https://doi.org/10.1182/blood-2023-180504

Published: 2023

Journal Articles

High Body Mass Index Is Associated with Favorable Outcome in Younger Patients Receiving CD19 CAR T-Cell Therapy for B-Cell Lymphoma: A Retrospective Study from the EBMT Transplant Complications Working Party

Blood (2023) 142 (Supplement 1): 4867.

https://doi.org/10.1182/blood-2023-187393

Published: 2023

Journal Articles

Graft-Versus-Host Disease after Anti-CD19 Chimeric Antigen Receptor T-Cell Infusion Post Allogeneic Hematopoietic Cell Transplantation: A Transplant Complications and Paediatric Disease Working Parties EBMT Joint Study

Blood (2023) 142 (Supplement 1): 2189.

https://doi.org/10.1182/blood-2023-177715

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide or ATG As Gvhd Prophylaxis in Mismatched Unrelated Stem Cell Transplantation? - a Registry Analysis By the EBMT Transplant Complications Working Party

Olaf Penack, Mouad Abouqateb, Christophe Peczynski, William Boreland, Zafer Gulbas, Tobias Gedde-Dahl, Cristina Castilla-Llorente, Nicolaus Kröger, Matthias Eder, Alessandro Rambaldi, Francesca Bonifazi, Igor Wolfgang Blau, Matthias Stelljes, Peter Dreger, Ivan Sergeevich Moiseev, Helene Schoemans, Christian Koenecke, Zinaida Peric

Blood (2023) 142 (Supplement 1): 2179.

https://doi.org/10.1182/blood-2023-179837

Published: 2023

Journal Articles

Clonal Hematopoiesis Is Common in Unrelated Stem Cell Donors but Has No Impact on Patient Outcome after Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 942.

https://doi.org/10.1182/blood-2023-179112

Published: 2023

Journal Articles

Severe Cytopenia after CD19 CAR T-Cell Therapy: A Retrospective Study from the EBMT Transplant Complications Working Party

Blood (2022) 140 (Supplement 1): 4664–4667.

https://doi.org/10.1182/blood-2022-168614

Published: 2022

Journal Articles

Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys

Blood (2022) 140 (Supplement 1): 10413–10415.

https://doi.org/10.1182/blood-2022-169037

Published: 2022

Journal Articles

Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study

Blood (2022) 140 (Supplement 1): 7734–7737.

https://doi.org/10.1182/blood-2022-168601

Published: 2022

Journal Articles

Association between Patient-Reported Social Determinant of Health Outcomes and a Social Genomics Profile in Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Mallory Taylor, Steve W. Cole, Joelle Strom, Ruta Brazauskas, K. Scott Baker, Rachel Phelan, David K. Buchbinder, Betty K. Hamilton, Helene Schoemans, Jennifer M Knight

Blood (2022) 140 (Supplement 1): 911–913.

https://doi.org/10.1182/blood-2022-162545

Published: 2022

Journal Articles

Validating a Machine Learning Grading System for Acute Gvhd. a Study on Behalf of the EBMT Transplant Complications Working Party

Amin T. Turki, Christophe Peczynski, Olaf Penack, Helene Schoemans, Gerard Socie, Christian Reinhardt, Nathalie Fegueux, Didier Blaise, Nicolaus Kröger, Stephan Mielke, Jan J. Cornelissen, Patrice Chevallier, Ibrahim Yakoub-Agha, Edouard Forcade, Grzegorz W Basak, Zinaida Perić

Blood (2021) 138 (Supplement 1): 1809.

https://doi.org/10.1182/blood-2021-147724

Published: 2021

Journal Articles

Management of Steroid-Refractory Graft-Versus-Host Disease - a Survey By the Transplant Complications Working Party of the EBMT

Zinaida Peric, Helene Schoemans, Christophe Peczynski, Christian Koenecke, Ivan S. Moiseev, Grzegorz W Basak, William Boreland, Hildegard T. Greinix, Daniel Wolff, Olaf Penack

Blood (2021) 138 (Supplement 1): 2884.

https://doi.org/10.1182/blood-2021-152305

Published: 2021

Journal Articles

Late Effects after Allogeneic Hematopoietic Cell Transplantation Among Children and Adolescents with Non-Malignant Disorders: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)

Justine M. Kahn, Stephanie Bo-Subait, David K. Buchbinder, Betty K. Hamilton, Helene Schoemans, Ruta Brazauskas, Rachel Phelan, Prakash Satwani

Blood (2021) 138 (Supplement 1): 412.

https://doi.org/10.1182/blood-2021-151446

Published: 2021

Journal Articles

One step at a time

Hélène Schoemans, Per Ljungman

Blood (2021) 138 (14): 1208–1209.

https://doi.org/10.1182/blood.2021013434

Published: 2021

Journal Articles

Conception and Pregnancy Outcomes after Haematopoietic Stem Cell Transplant: A Retrospective Study from the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation

Blood (2018) 132 (Supplement 1): 2139.

https://doi.org/10.1182/blood-2018-99-113643

Published: 2018

Journal Articles

Impact of Upfront Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma with Del(17) and t(4;14): A Report from the EBMT Chronic Malignancies Working Party

Blood (2018) 132 (Supplement 1): 2143.

https://doi.org/10.1182/blood-2018-99-115372

Published: 2018

Journal Articles

Metabolic Syndrome Is Common Following Haematopoietic Cell Transplantation (HCT) and Is Associated with Increased Cardiovascular Disease and Second Cancers: An EBMT Cross-Sectional Non-Interventional Study

Blood (2018) 132 (Supplement 1): 251.

https://doi.org/10.1182/blood-2018-99-116533

Published: 2018

Journal Articles

The Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: An Analysis By the EBMT Complications and Quality of Life WP

Blood (2017) 130 (Supplement 1): 3324.

https://doi.org/10.1182/blood.V130.Suppl_1.3324.3324

Published: 2017

Journal Articles

Ibrutinib for Bridging to Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Is Safe and Effective: First Results of a Survey By the Chronic Malignancy and the Lymphoma Working Parties of the EBMT

Blood (2016) 128 (22): 4657.

https://doi.org/10.1182/blood.V128.22.4657.4657

Published: 2016

NARROW

Practice Patterns of SGLT2 Inhibitor Use in Stem Cell Transplantation and CART Cell Therapy: A Study from the EBMT Transplant Complications Working Party

Developing Evidence-Based Guidelines for Optimal Patient Communication Prior and Post Allogeneic Stem Cell Transplantation

ATG or Post-Transplant Cyclophosphamide to Prevent Gvhd in Matched Unrelated Stem Cell Transplantation? - a Registry Analysis By the EBMT Transplant Complications Working Party

High Body Mass Index Is Associated with Favorable Outcome in Younger Patients Receiving CD19 CAR T-Cell Therapy for B-Cell Lymphoma: A Retrospective Study from the EBMT Transplant Complications Working Party

Graft-Versus-Host Disease after Anti-CD19 Chimeric Antigen Receptor T-Cell Infusion Post Allogeneic Hematopoietic Cell Transplantation: A Transplant Complications and Paediatric Disease Working Parties EBMT Joint Study

Post-Transplant Cyclophosphamide or ATG As Gvhd Prophylaxis in Mismatched Unrelated Stem Cell Transplantation? - a Registry Analysis By the EBMT Transplant Complications Working Party

Clonal Hematopoiesis Is Common in Unrelated Stem Cell Donors but Has No Impact on Patient Outcome after Hematopoietic Stem Cell Transplantation

Severe Cytopenia after CD19 CAR T-Cell Therapy: A Retrospective Study from the EBMT Transplant Complications Working Party

Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys

Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study

Association between Patient-Reported Social Determinant of Health Outcomes and a Social Genomics Profile in Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Validating a Machine Learning Grading System for Acute Gvhd. a Study on Behalf of the EBMT Transplant Complications Working Party

Management of Steroid-Refractory Graft-Versus-Host Disease - a Survey By the Transplant Complications Working Party of the EBMT

Late Effects after Allogeneic Hematopoietic Cell Transplantation Among Children and Adolescents with Non-Malignant Disorders: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)

One step at a time

Conception and Pregnancy Outcomes after Haematopoietic Stem Cell Transplant: A Retrospective Study from the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation

Impact of Upfront Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma with Del(17) and t(4;14): A Report from the EBMT Chronic Malignancies Working Party

Metabolic Syndrome Is Common Following Haematopoietic Cell Transplantation (HCT) and Is Associated with Increased Cardiovascular Disease and Second Cancers: An EBMT Cross-Sectional Non-Interventional Study

The Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: An Analysis By the EBMT Complications and Quality of Life WP

Ibrutinib for Bridging to Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Is Safe and Effective: First Results of a Survey By the Chronic Malignancy and the Lymphoma Working Parties of the EBMT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only